Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
about
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillationAntiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillationAntiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillationRisk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillationAzimilide dihydrochloride: a new class III anti-arrhythmic agent.Management of the older person with atrial fibrillation.Atrial Fibrillation: The New Epidemic of the Ageing WorldData-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management.What should we expect from the next generation of antiarrhythmic drugs?Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa)Management of the older person with ventricular arrhythmias.Dofetilide, a new class III antiarrhythmic agent.Antiarrhythmics--from cell to clinic: past, present, and future.Antiarrhythmic drugs: from mechanisms to clinical practice.Efficacy of Cox Maze IV Procedure Using Argon-Based Cryoablation: A Comparative Study with N2O-Based Cryoablation.Atrial fibrillation pearls and perils of managementRole of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias.Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials.Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillationStructural bases for the different anti-fibrillatory effects of chloroquine and quinidine.Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillationAblate and pace revisited: long term survival and predictors of permanent atrial fibrillation.Antiadrenergic therapy in the control of atrial fibrillation.Effects of Na+ channel blockers on the restitution of refractory period, conduction time, and excitation wavelength in perfused guinea-pig heartModern management of arrhythmias.Pharmacotherapy changes following pacemaker implantation in patients with bradycardia-tachycardia syndrome.Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.Initial experience with single lead intracardial cardioversion for refractory atrial fibrillation.Vernakalant in the management of atrial fibrillation.An Update on the Energy Sources and Catheter Technology for the Ablation of Atrial Fibrillation.Atrial fibrillation after cardiac surgery: does prophylactic therapy decrease adverse outcomes associated with atrial fibrillation.Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation.Atrial fibrillation and heart failure in the elderly.Management of ventricular and atrial arrhythmias in humans: towards a patient-specific approach.A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.The efficacy and tolerability of commonly used agents to prevent recurrence of atrial fibrillation after successful cardioversion.Genotype influence in responses to therapy for atrial fibrillation.Atrial Fibrillation Ablation: First-Line Therapy?Role of abnormal repolarization in the mechanism of cardiac arrhythmia.
P2860
Q24187110-066FEF8C-B861-487D-8B43-229F0DF67B94Q24197643-20A5333D-2B33-45DC-A589-26E3F3B0F762Q24243067-2F54E6FC-C628-4073-9863-839C77CF9698Q24804548-432764D6-A57D-47E0-85C4-B477E513AC6EQ31522245-5B00CE99-5D0F-431B-843C-3028464B38EFQ33144789-917B073A-EEDE-4EA4-88C7-58A5683590FEQ33168630-B4CD0FB8-B2D0-4BC7-BD15-BBFC2F071C2BQ33179799-37E9095B-FF91-405A-B339-963969C07684Q33544553-F6867B6C-CBC5-463F-BCAA-D54A6184EB8FQ33552973-C602BF1B-5953-4F48-91D1-F18BA483EAFCQ33686613-C8E825EB-E69A-4850-9313-6AC44C11C9B2Q33910947-C62D0115-8806-48A3-B24F-9FAC21EF4099Q33947683-FEEA8C9F-BB07-41D8-840F-6251C28AD420Q34012641-37325055-2091-4322-BF07-248AFAD9406EQ34148372-AACC30D6-7F61-4815-A083-4C9881C73361Q34183370-32D354A6-26CF-4B2E-9C76-1959A16FBA4CQ34249396-EEFAE17D-85FA-456A-BF48-ED6BC3E3ED2FQ34308117-394172DC-7892-4EEE-A4B7-58959D98EDF0Q34496116-810FDD85-FF00-4917-8A3D-A1D1E6A89955Q34523170-AAE4E078-5E5C-44B4-AB82-088D4F0A7380Q34575313-78912F49-DA52-4C62-B759-4CD4DF7C2C05Q35565932-65199CFC-0E91-448A-A06A-04AA44EB3D25Q35581534-2734A1B7-3B81-4332-B12D-A76436657283Q36167685-F1C63229-E3D6-4115-A470-FDD5C5CEA1BEQ36288597-AD6EFA43-2751-4900-A29A-02C480EDFE21Q36388570-69AD7F3F-C954-4100-A0FA-E3F8B359339BQ36632222-2502F2D7-3F53-4CCF-99D4-7272D184CCC1Q36764028-DD57ED01-81FB-4409-9F32-02343A245E4EQ36817122-E245DAA9-83F9-44AE-87CA-E8F30DFC6E0BQ37107714-9465084C-8300-4276-81BF-F5A17892776EQ37114816-9042876F-CA36-4E98-88F7-F09404EC0AF1Q37328758-89A49AEC-6759-4965-91C1-5DEE851E51DDQ37417705-55F97B62-C37B-400F-96EF-F8B36BA0CF9EQ37952604-F5893A77-80D7-4D8C-9562-F6E2EABAB819Q38056113-AB6B470C-2A68-4E8E-86C8-4B9CDD584FAAQ38080598-C01BC449-EA96-416A-9B86-4F0C77A122BCQ38194112-F7163EA7-C7BC-4F98-9AF5-DEA47EB6A6BBQ38894994-52B06C8B-350C-4CE9-82A9-EF9AA1CFAF3FQ39300446-1158E827-3911-4F7F-9FA7-7128C769F94EQ39434566-00CE45FA-1DF9-4E5E-8488-89C0F00A38CC
P2860
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Antiarrhythmic drug therapy an ...... al Fibrillation Investigators.
@ast
Antiarrhythmic drug therapy an ...... al Fibrillation Investigators.
@en
type
label
Antiarrhythmic drug therapy an ...... al Fibrillation Investigators.
@ast
Antiarrhythmic drug therapy an ...... al Fibrillation Investigators.
@en
prefLabel
Antiarrhythmic drug therapy an ...... al Fibrillation Investigators.
@ast
Antiarrhythmic drug therapy an ...... al Fibrillation Investigators.
@en
P2093
P1476
Antiarrhythmic drug therapy an ...... al Fibrillation Investigators.
@en
P2093
Blackshear JL
Halperin JL
Kronmal RA
P304
P356
10.1016/0735-1097(92)90003-6
P407
P577
1992-09-01T00:00:00Z